(Total Views: 500)
Posted On: 05/05/2025 1:58:13 PM
Post# of 154593
Hijacked AI excerpt from a post by livimune on Reddit concerning possible/plausible additional MOA actions/discussions at upcoming ESMO.
Excellent AI effort. Well worth a read.
https://www.reddit.com/r/Livimmune/comments/1...yond_ccr5/
"Leronlimab, by occupying CCR5 on TNBC cells, likely prevents CCR5-mediated chemotaxis and tissue homing. This anti-metastatic action could curb the seeding of new tumor lesions. Indeed, CCR5 inhibition not only prevented the formation of metastases but also slowed the progression of established metastatic disease in murine TNBC modelsbreast-cancer-research.biomedcentral.com. Such an effect aligns with clinical observations of extended progression-free intervals in Leronlimab-treated patientstargetedonc.comtargetedonc.com. By blocking CCR5-dependent invasion pathways, Leronlimab may halt the cascade of metastasis – an important mechanism to explain improved survival in metastatic TNBC
Excellent AI effort. Well worth a read.
https://www.reddit.com/r/Livimmune/comments/1...yond_ccr5/
"Leronlimab, by occupying CCR5 on TNBC cells, likely prevents CCR5-mediated chemotaxis and tissue homing. This anti-metastatic action could curb the seeding of new tumor lesions. Indeed, CCR5 inhibition not only prevented the formation of metastases but also slowed the progression of established metastatic disease in murine TNBC modelsbreast-cancer-research.biomedcentral.com. Such an effect aligns with clinical observations of extended progression-free intervals in Leronlimab-treated patientstargetedonc.comtargetedonc.com. By blocking CCR5-dependent invasion pathways, Leronlimab may halt the cascade of metastasis – an important mechanism to explain improved survival in metastatic TNBC
(4)
(0)
